EnteroMedics Inc. (NASDAQ: ETRM) 72.3% LOWER; announced preliminary results from its EMPOWER Study. Based on an initial analysis, the study did not meet its primary and secondary efficacy endpoints. There were no therapy-related serious adverse events reported in the study. The EMPOWER Study is a randomized, double-blind, placebo-controlled pivotal study designed to evaluate the safety and effectiveness of the Maestro(R) System for the treatment of obesity.

Bionovo, Inc. (Nasdaq: BNVI) 24.9% LOWER; today announced that it has entered into agreements with selected investors to sell up to 3,230,995 units at a price per unit of $6.20 for aggregate gross